Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-cash Items (2016 - 2025)

CytomX Therapeutics' Non-cash Items history spans 12 years, with the latest figure at $7.3 million for Q4 2025.

  • For Q4 2025, Non-cash Items fell 30.91% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $7.3 million, down 30.91%, while the annual FY2025 figure was $7.3 million, 30.91% down from the prior year.
  • Non-cash Items reached $7.3 million in Q4 2025 per CTMX's latest filing, down from $10.6 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $14.2 million in Q4 2022 to a low of $1.2 million in Q4 2021.
  • Average Non-cash Items over 5 years is $7.3 million, with a median of $6.5 million recorded in 2021.
  • Peak YoY movement for Non-cash Items: plummeted 80.77% in 2021, then surged 1105.58% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $1.2 million in 2021, then soared by 1105.58% to $14.2 million in 2022, then crashed by 39.14% to $8.7 million in 2023, then grew by 21.84% to $10.6 million in 2024, then tumbled by 30.91% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Non-cash Items are $7.3 million (Q4 2025), $10.6 million (Q4 2024), and $8.7 million (Q4 2023).